(Q37257466)

English

Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension

scientific article published on 08 February 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension (English)

1 reference

Europe PubMed Central

19 August 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

S-M Jin

1

1 reference

Europe PubMed Central

19 August 2017

C-Y Park

2

1 reference

Europe PubMed Central

19 August 2017

Y M Cho

3

1 reference

Europe PubMed Central

19 August 2017

B J Ku

4

1 reference

Europe PubMed Central

19 August 2017

C W Ahn

5

1 reference

Europe PubMed Central

19 August 2017

B-S Cha

6

1 reference

Europe PubMed Central

19 August 2017

K W Min

7

1 reference

Europe PubMed Central

19 August 2017

Y A Sung

8

1 reference

Europe PubMed Central

19 August 2017

S H Baik

9

1 reference

Europe PubMed Central

19 August 2017

K W Lee

10

1 reference

Europe PubMed Central

19 August 2017

K-H Yoon

11

1 reference

Europe PubMed Central

19 August 2017

M-K Lee

12

1 reference

Europe PubMed Central

19 August 2017

S W Park

13

1 reference

Europe PubMed Central

19 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

8 February 2015

1 reference

Europe PubMed Central

19 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

19 August 2017

17

1 reference

Europe PubMed Central

19 August 2017

6

1 reference

Europe PubMed Central

19 August 2017

599-602

1 reference

Europe PubMed Central

19 August 2017

Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

6 September 2017

Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

6 September 2017

CKD-501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

6 September 2017

Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

6 September 2017

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

6 September 2017

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

6 September 2017

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

6 September 2017

Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

14 September 2017

Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

26 June 2018

Carcinogenicity study of CKD-501, a novel dual peroxisome proliferator-activated receptors α and γ agonist, following oral administration to Sprague Dawley rats for 94-101 weeks.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

3 September 2018

Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024060

3 September 2018

Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25580775

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/DOM.12435

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37257466&oldid=2138391820"